October 23, 2019 News by Alejandra Viviescas, PhD NfL and CHI3L1 Work as Biomarkers of Disease Activity and Progression in MS, Study Says The levels ofĀ neurofilament light chainĀ (NfL) and chitinase3-like1 (CHI3L1) in the cerebrospinal fluid ā the liquid that surrounds the brain and spinal cord ā serve as respective biomarkers of disease activity and progression in multiple sclerosis (MS), a study reports. Measuring levels of both proteins also helps to…
September 27, 2019 News by Mary Chapman Michiganās Memorial Healthcare First in US to Test NfL in MS Patients Memorial Healthcare Institute for Neurosciences and Multiple SclerosisĀ announced it will become the first U.S. hospital to test a nerve cell-derived component known as neurofilament light chain (NfL) in multiple sclerosis (MS) patients. Led by the Owosso, Michigan, hospitalās chief of neurology and MS director, Rany Aburashed, DO,…
September 16, 2019 News by Jose Marques Lopes, PhD #ECTRIMS2019 ā Glia Score May Differentiate Progressive MS from RRMS, Study Suggests Patients with progressive multiple sclerosis (MS) have higher levels of protein markers of activated glial cells than those with relapsing-remitting MS (RRMS) or patients with other neurological disorders, according to a new study. The findings also indicated that scoring the extent of glial involvement in relation to nerve…
September 16, 2019 News by Patricia Inacio, PhD #ECTRIMS2019 – Nerve Cell Damage May Be Evident Years Before Symptoms Are Damage to nerve cells appears to occur years before people with multiple sclerosis (MS) begin to show symptoms and is evident in a likely biomarker, new data suggest. Researchers found raised levels of neurofilament light chain (NfL), a protein associated with nerve cell damage, in blood samples collected six years…
September 16, 2019 News by Patricia Inacio, PhD #ECTRIMS2019 – Anti-epileptic May Help to Stop Disability Progression, Study Suggests Oxcarbazepine, an anti-epileptic medicine, given in combination with a disease-modifying therapy (DMT) may help to stop disability progression in multiple sclerosis (MS) patients, results of Phase 2 trial suggest. Monica Marta, PhD, withĀ Queen Mary University of LondonĀ and Barts Health NHS Trust/The Royal London HospitalĀ presented the data at the…
July 8, 2019 News by Jose Marques Lopes, PhD Mayzent Boosts Cognitive Processing Speed in SPMS Patients, Phase 3 Trial Data Show Treatment with Mayzent (siponimod) led to significant improvement in cognitive processing speed in patients with secondary progressive multiple sclerosis (SPMS), according to updated results of a Phase 3 trial. Novartisā findings, presented at the European Academy of Neurology (EAN) congressĀ that ran June 29āJuly 2 in Oslo,…
May 8, 2019 News by Ana Pena PhD #AANAM ā Quanterix Leads Research on Neurofilament Light Chain as Potential MS Biomarker Quanterix is leading the research presented at this year’s American Academy of Neurology (AAN) Annual Meeting, validating the use of neurofilament light chain (NfL) as a potential biomarker for the diagnosis, prognosis, and treatment monitoring of patients with multiple sclerosis (MS) and other neurodegenerative diseases. The company…
February 15, 2019 News by Jonathan Grinstein Neurofilament Light Chain Levels in Blood of Value as Biomarker of MS Activity and Treatment Response, Study Finds Blood levels of a nerve cell-derived component known as neurofilament light chain (NfL) could be used as a biomarker of disease severity and treatment response in patients with relapsing-remitting multiple sclerosis (RRMS), a new study shows. The research article, āBlood neurofilament light chain as a biomarker of MS…
October 17, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Blood Level of Neurofilament Light Chain May Predict Brain Atrophy in Progressive MS, Study Suggests Measuring the blood level of neurofilament light chain (NfL) may predict brain shrinkage in primary progressive (PPMS) and secondary progressive multiple sclerosis (SPMS), according to a new study. The findings also show that NfL levels are associated with brain lesion load in these patients. The research, ā…
October 15, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 – Plasma Neurofilament Light Levels Linked to Treatment Effects in RRMS, Study Finds Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) inĀ relapsing-remitting multiple sclerosisĀ (RRMS) patients, according to a real-world study. Study findings also revealed that treatment with either Lemtrada (alemtuzumab, marketed byĀ Sanofi Genzyme),Ā Gilenya (fingolimod, marketed by Novartis), Tecfidera (dimethyl fumarate, marketed…
September 5, 2018 News by Patricia Inacio, PhD Higher Levels of Neurofilament Light Chain in Blood and Cerebrospinal Fluid Found in MS Patients, Supporting its Prognostic Potential A meta-analysis of 13 case-control studies shows that the levels of the protein neurofilament light chain (NFL) are significantly higher in both the cerebrospinal fluid and blood of multiple sclerosis (MS) patients, compared to healthy controls. This findingĀ adds to previous evidence supporting the usefulness of NFL as a…
August 8, 2018 News by Alice MelĆ£o, MSc Quanterixās Simoa Assay May Make Neurofilament Light Chain Useful Blood Biomarker of MS and Its Likely Progression Quanterixās ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament light chain, including the possibility to detect early evidence of neurological diseases like multiple sclerosis (MS),Ā Parkinsonās, and Alzheimerās, and ably evaluate efforts to treat and prevent them,Ā the company…
July 24, 2018 News by Ana Pena PhD Cerebrospinal Fluid Neurofilament Predicts CIS and RRMS Progression, Study Contends Cerebrospinal fluid levels of neurofilament light chain, a protein associated with nerve cell damage, can predict disease progression in people with clinical isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS), a Swedish study found. Higher levels…
July 17, 2018 News by Alice MelĆ£o, MSc Progressive MS Patients with Considerable Disability Ably Treated with Cladribine, UK Case Study Reports Cladridine may be effective in preventingĀ disability progression and reducing damage to nerve cells in people withĀ progressive forms of multiple sclerosis (MS), researchers suggest based on a case study of two such patients given the injectable treatment. MS is characterized by progressive degeneration of cells in the central nervous system, mostly…
June 20, 2018 News by Patricia Inacio, PhD #EAN2018 – Levels ofĀ Neurofilament Light Chain Can Predict Disease Progression in RRMS, Study Shows Levels ofĀ neurofilament light chain are a reliable predictor of disease worsening and progression in relapsing-remitting MS (RRMS) patients, a new study shows. Moreover, treatment withĀ GilenyaĀ (fingolimod), marketed by Novartis, can reduce the levels ofĀ NfL for up to 10 years. These findings were shared recently in the presentation ā…
April 18, 2018 News by Patricia Inacio, PhD #AAN2018 – Ocrevus Decreases Biomarkers of MS Patients’ Nerve Cell Damage, Phase 3 Trial Shows Genentech’sĀ Ocrevus (ocrelizumab)Ā reduces levels of cerebrospinal fluid biomarkers that denote nerve cell damage in multiple sclerosis patients, a Phase 3 clinical trial shows. Researchers will present the results at theĀ American Academy of Neurology’s annual meetingĀ in Los Angeles, April 21-27. The presentation will be titled āInterim Analysis of the…
December 4, 2017 News by Patricia Silva, PhD Blood Test That Helps Predict MS Disease Activity Might Lower Need for MRI Scans, Study Suggests A blood test may someday replace some of the magnetic resonance imaging (MRI) scans taken by people with multiple sclerosis (MS) Ā ā offering an easy, cheap alternative for monitoring disease activity. A study by Norway’s University of BergenĀ found that blood levels of a factor called neurofilament light chain, released…